Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal residual disease (MRD) in non-Hodgkin lymphomas: Interlaboratory reproducibility on marrow samples with very low levels of disease within the FIL (Fondazione Italiana Linfomi) MRD Network.
Della Starza I, Cavalli M, De Novi LA, Genuardi E, Mantoan B, Drandi D, Barbero D, Ciabatti E, Grassi S, Gazzola A, Mannu C, Agostinelli C, Piccaluga PP, Bomben R, Degan M, Gattei V, Guarini A, Foà R, Galimberti S, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: mantoan b. Hematol Oncol. 2019 Oct;37(4):368-374. doi: 10.1002/hon.2652. Epub 2019 Aug 16. Hematol Oncol. 2019. PMID: 31325190
Comparison of two real-time quantitative polymerase chain reaction strategies for minimal residual disease evaluation in lymphoproliferative disorders: correlation between immunoglobulin gene mutation load and real-time quantitative polymerase chain reaction performance.
Della Starza I, Cavalli M, Del Giudice I, Barbero D, Mantoan B, Genuardi E, Urbano M, Mannu C, Gazzola A, Ciabatti E, Guarini A, Foà R, Galimberti S, Piccaluga P, Gaidano G, Ladetto M, Monitillo L. Della Starza I, et al. Among authors: mantoan b. Hematol Oncol. 2014 Sep;32(3):133-8. doi: 10.1002/hon.2095. Epub 2013 Nov 19. Hematol Oncol. 2014. PMID: 24254547
Comparison of different DNA extraction methods from peripheral blood cells: advice from the Fondazione Italiana Linfomi Minimal Residual Disease Network.
Mannu C, Gazzola A, Ciabatti E, Fuligni F, Cavalli M, Della Starza I, Genuardi E, Mantoan B, Monitillo L, Del Giudice I, Ladetto M, Gaidano G, Sabattini E, Pileri SA, Galimberti S, Piccaluga PP; Fondazione Italiana Linfomi Minimal Residual Disease Network. Mannu C, et al. Among authors: mantoan b. Leuk Lymphoma. 2016 Feb;57(2):400-410. doi: 10.3109/10428194.2014.914199. Epub 2015 Mar 11. Leuk Lymphoma. 2016. PMID: 25115509
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial.
Galimberti S, Luminari S, Ciabatti E, Grassi S, Guerrini F, Dondi A, Marcheselli L, Ladetto M, Piccaluga PP, Gazzola A, Mannu C, Monitillo L, Mantoan B, Del Giudice I, Della Starza I, Cavalli M, Arcaini L, Tucci A, Palumbo GA, Rigacci L, Pulsoni A, Vitolo U, Boccomini C, Vallisa D, Bertoldero G, Gaidano G, Musto P, Petrini M, Federico M. Galimberti S, et al. Among authors: mantoan b. Clin Cancer Res. 2014 Dec 15;20(24):6398-405. doi: 10.1158/1078-0432.CCR-14-0407. Epub 2014 Oct 14. Clin Cancer Res. 2014. PMID: 25316810 Free article.
Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma.
Della Starza I, De Novi LA, Cavalli M, Novelli N, Soscia R, Genuardi E, Mantoan B, Drandi D, Ferrante M, Monitillo L, Barbero D, Ciabatti E, Grassi S, Bomben R, Degan M, Gattei V, Galimberti S, Di Rocco A, Martelli M, Cortelazzo S, Guarini A, Foà R, Ladetto M, Ferrero S, Del Giudice I; Fondazione Italiana Linfomi (FIL) MRD Network. Della Starza I, et al. Among authors: mantoan b. Hematol Oncol. 2020 Dec;38(5):698-704. doi: 10.1002/hon.2792. Epub 2020 Aug 28. Hematol Oncol. 2020. PMID: 32816326
Targeted locus amplification to detect molecular markers in mantle cell and follicular lymphoma.
Genuardi E, Klous P, Mantoan B, Drandi D, Ferrante M, Cavallo F, Alessandria B, Dogliotti I, Grimaldi D, Ragaini S, Clerico M, Lo Schirico M, Saraci E, Yilmaz M, Zaccaria GM, Cortelazzo S, Vitolo U, Luminari S, Federico M, Boccadoro M, van Min M, Splinter E, Ladetto M, Ferrero S. Genuardi E, et al. Among authors: mantoan b. Hematol Oncol. 2021 Aug;39(3):293-303. doi: 10.1002/hon.2864. Epub 2021 Mar 31. Hematol Oncol. 2021. PMID: 33742718 Free PMC article. Clinical Trial.
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program.
Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Ladetto M, et al. Among authors: mantoan b. Blood. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. Blood. 2013. PMID: 24085766 Free article. Clinical Trial.
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R, Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P, Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U, Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M. Drandi D, et al. Among authors: mantoan b. J Mol Diagn. 2015 Nov;17(6):652-60. doi: 10.1016/j.jmoldx.2015.05.007. Epub 2015 Aug 28. J Mol Diagn. 2015. PMID: 26319783 Free article.
45 results